Automated Tissue Microarray Validation via Image Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for validating the quality of tissue microarrays and whole tissue sections are manual, time-consuming, and prone to subjective variability, lacking standardization and efficiency in assessing the quality of histological tissue specimens before analytical analysis.
Innovation Solution
An automated system and method that uses a microscope with an image sensor and processor to evaluate the quality of slide-mounted tissue samples by determining quantitative quality indicators such as staining uniformity, tissue integrity, and image integrity, allowing for rapid validation and reducing reviewer subjectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual validation methods are used to assess tissue microarray quality, then pathologists can subjectively evaluate each histospot, but the process is extremely time-consuming (8+ hours for 700 spots) and lacks consistency
Solution Approach 1:
The patent replaces the manual mechanical inspection process with an automated digital image analysis system. The system uses computer algorithms to objectively evaluate tissue microarray images, replacing the pathologist's subjective visual assessment. This substitution eliminates the time-consuming manual review process while maintaining or improving assessment consistency through standardized automated criteria.
Solution Approach 2:
The validation system performs self-assessment of tissue microarray quality without requiring extensive manual intervention. The automated algorithm independently evaluates each histospot for quality metrics such as staining uniformity, tissue integrity, and artifact presence, enabling the system to serve its own validation function without continuous human oversight.
2Ease of operation
If manual validation is performed by pathologists, then quality assessment can be done, but reviewer subjectivity leads to inconsistent results
Solution Approach 1:
The patent transforms subjective quality assessment into objective parameter-based evaluation. Instead of relying on pathologist judgment, the system measures specific parameters such as staining intensity, uniformity, and tissue morphology metrics. These quantifiable parameters provide consistent, reproducible results that eliminate reviewer subjectivity while maintaining operational simplicity through automated processing.
3Manufacturing precision
If traditional tissue analysis techniques are used, then each tissue sample can be analyzed individually, but tissue resources are wasted and reagent consumption is high
Solution Approach 1:
The patent merges multiple tissue samples into a single tissue microarray construct, allowing simultaneous analysis of numerous histospots on one slide. This consolidation reduces the total amount of tissue required and minimizes reagent consumption compared to analyzing each sample separately on individual slides, while maintaining analytical precision through standardized processing conditions.
Solution Approach 2:
The tissue microarray platform serves multiple analytical functions simultaneously. A single slide containing hundreds of histospots can be used to evaluate numerous tissue samples under identical conditions, making the system universally applicable for high-throughput validation studies while efficiently utilizing scarce tissue resources and reducing overall reagent requirements.
Data Source
AI summary
A method and system for automatically evaluating quality of a slide-mounted tissue sample includes receiving a digital image of a magnified portion of the slide-mounted tissue sample. At least one quantitative quality indicator is automatically determined for at least one of the samples, and the digital image of the magnified portion of the sample. Each of the quantitative quality indicators is automatically compared to a respective minimum acceptable quality threshold. The quantitative quality indicators and associated quality thresholds are selected for suitability with an automated quantitative immunoassay. Failure of one or more of the quantitative quality indicators to meet its respective minimum acceptable quality threshold suggests that the sample is unsuitable for subsequent automated pathological evaluation. Results can be examined at a user interface allowing for user inspection of samples determined to be unsuitable, the user interface also having provisions for manual override of the determination.